Data released from the Comparison of AMD Treatment Trials (CATT), and published in in the journal Ophthalmology (Vol. 120, No. 3, pp593-99), suggest that while specific alleles for CFH, ARMS2, HTRA1 and C3 may predict AMD development, they do not predict the pharmacogenetic response to anti-VEGF therapies. The research found no statistically significant differences in response by genotype for a range of clinical measures assessed, including mean visual acuity (VA), changes in VA, retinal thickness, changes in total foveal thickness, presence of leakage on fluorescein angiography (FA) and changes in lesion size. In addition, response to therapy did not vary by the number of risk alleles present and clinical outcomes were similar between groups treated with either Avastin or Lucentis, monthly or pro re nata dosing.